| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T230 |
90-131 |
Sentence |
denotes |
Open-label RCT (NCT04244591, recruiting). |
| T231 |
132-198 |
Sentence |
denotes |
Primary endpoint: lower Murray lung injury score at days 7 and 14. |
| T232 |
199-281 |
Sentence |
denotes |
• Comparison of methylprednisolone vs. standard of care in patients with COVID-19. |
| T233 |
282-323 |
Sentence |
denotes |
Open-label RCT (NCT04273321, recruiting). |
| T234 |
324-380 |
Sentence |
denotes |
Primary endpoint: treatment failure (follow-up 14 days). |
| T235 |
381-581 |
Sentence |
denotes |
• Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus methylprednisolone plus umifenovir in patients with severe COVID-19. |
| T236 |
582-633 |
Sentence |
denotes |
Double-blind RCT (NCT04273581, not yet recruiting). |
| T237 |
634-701 |
Sentence |
denotes |
Primary endpoint: time to clinical improvement (follow-up 28 days). |
| T238 |
702-784 |
Sentence |
denotes |
• Comparison of different dosages of methylprednisolone in patients with COVID-19. |
| T239 |
785-826 |
Sentence |
denotes |
Open-label RCT (NCT04263402, recruiting). |
| T240 |
827-908 |
Sentence |
denotes |
Primary endpoints: (a) disease readmission at day 7; (b) critical stage at day 7. |
| T241 |
909-1017 |
Sentence |
denotes |
• Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. |
| T242 |
1018-1067 |
Sentence |
denotes |
Open-label RCT (NCT04329650, not yet recruiting). |
| T243 |
1068-1119 |
Sentence |
denotes |
Primary endpoint: ICU admission (follow-up 29 days) |
